13.7 C
New York
Saturday, December 3, 2022

Latest Posts

What should be known about the drug that slows the worsening of Alzheimer’s?

- Advertisement -

In recent days, the results of the phase 3 study of an experimental drug to treat Alzheimer’s and slow down its degeneration were released.

Apparently this sheds light on curbing the attacks of the degenerative disease that is characterized by the death of brain cells and maintains a deterioration of cognitive abilities, memory, among others. So far there is no cure for the disease, but there are drugs that help delay progression, one of which is proposed is lecanemab.

- Advertisement -

Early signs of Alzheimer’s disease

The Japanese pharmaceutical Eisai and the American Biogen announced the results of the third-phase clinical trial that was carried out with the new treatment.

According to the companies’ statement, the drug is an antibody that was used to treat mild cognitive impairment in the disease. “Lecanemab met the primary endpoint,” it said.

- Advertisement -

Through a numerical scale to quantify the diversity of the severity of dementia symptoms. The trial started in 2019 and involved 1,795 people from Japan, the United States and Europe. Two groups of patients were divided, one was given the drug for 18 months and the other a placebo.

The treatment reduced clinical deterioration by 27%.

When Alzheimer’s runs in the family, how can children overcome the fear of receiving the same diagnosis?

“Clarity AD was a worldwide confirmatory Phase 3, randomized, double-blind, parallel-group study in 1,795 people with early AD. The treatment group was given a 10 mg/kg every other week dose of lecanemab, and participants were assigned in a 1:1 ratio to receive placebo or lecanemab,” the report stated.

The study identified that removal of aggregated amyloid beta in the brain helps slow down the disease in previously early-stage patients.

Participants included those with high blood pressure, diabetes, heart disease, obesity, kidney disease, and blood thinners.

By March 2023, it is expected that the approval of the drug will be requested in the test sites. (YO)

Source: Eluniverso

- Advertisement -

Latest Posts

Don't Miss

Stay in touch

To be updated with all the latest news, offers and special announcements.